Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35(21):2410–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Green K, Munakomi S, Hogg JP. Central Nervous System Lymphoma. [Updated 2024 May 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545145/

Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol. 2016;174(3):417–24.

Article  PubMed  PubMed Central  Google Scholar 

Kaulen LD, Baehring JM. Treatment options for recurrent primary CNS lymphoma. Curr Treat Options Oncol. 2022;23(11):1548–65.

Article  PubMed  Google Scholar 

Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, et al. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol. 2016;131(6):865–75.

Article  CAS  PubMed  Google Scholar 

Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)–a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008;49 Suppl 1(0 1):43–51.

Article  PubMed  Google Scholar 

Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203–11.

Article  CAS  PubMed  Google Scholar 

Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun. 2022;13(1):2558.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42(3):279–90.

Article  CAS  PubMed  Google Scholar 

Wen R, Wang D. MCD-DLBCL arises from germinal center B cells. Blood. 2022;140(10):1058–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grommes C, Nayak L, Tun HW, Batchelor TT. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol. 2019;21(3):306–13.

Article  PubMed  Google Scholar 

Minderman M, Amir A, Kraan W, Schilder-Tol EJM, Oud M, Scheepstra CG, et al. Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations. Blood. 2021;138(13):1194–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chukwueke U, Grommes C, Nayak L. Primary central nervous system lymphomas. Hematol Oncol Clin North Am. 2022;36(1):147–59.

Article  PubMed  Google Scholar 

Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20.

Article  CAS  PubMed  Google Scholar 

Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18(4):1146–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217–27.

Article  PubMed  Google Scholar 

Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van’t Veer M, Hansen M, Soubeyran P, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21(24):4483–8.

Article  CAS  PubMed  Google Scholar 

Adhikari N, Biswas A, Gogia A, Sahoo RK, Garg A, Nehra A, et al. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. J Neurooncol. 2018;139(1):153–66.

Article  CAS  PubMed  Google Scholar 

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36(7):1870–8.

Article  CAS  PubMed  Google Scholar 

Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molucon-Chabrot C, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. J Clin Oncol. 2022;40(32):3692–8.

Article  CAS  PubMed  Google Scholar 

Pentsova E, Deangelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol. 2014;117(1):161–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dietrich J, Versmee L, Drappatz J, Eichler AF, Nayak L, Norden A, et al. Pemetrexed in recurrent or progressive central nervous system lymphoma: A Phase I Multicenter Clinical Trial. Oncologist. 2020;25(9):747-e1273.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26(15):2512–8.

Article  PubMed  Google Scholar 

Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, et al. A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Adv. 2021;5(20):4073–82.

Article  CAS  PubMed  PubMed Central